Stay updated on Faricimab in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.

Latest updates to the Faricimab in Neovascular AMD Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdministrative updates to the study page, including the last update posted date and minor text edits in the Study Overview and Study Record. These changes do not affect the study's design, eligibility criteria, outcomes, or results.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference0.9%

- Check46 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.0%

- Check60 days agoChange DetectedThe update primarily localizes the location label to 'México' (instead of 'Mexico') while preserving the rest of the address; the page revision is bumped to v3.0.2. A non-critical navigation element 'Back to Top' was removed.SummaryDifference0.1%

- Check67 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

- Check75 days agoChange DetectedThe webpage has undergone significant updates, including the addition of various facility names and locations across multiple countries, while also removing several previously listed locations and related topics. Notably, the names of drugs such as faricimab and aflibercept have been retained, indicating a focus on specific treatments.SummaryDifference2%

Stay in the know with updates to Faricimab in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.